Bioadaptives (BDPT) Return on Sales (2016 - 2026)

Bioadaptives has disclosed Return on Sales across 9 years of filings, most recently posting 0.2% for Q1 2026.

• Return on Sales for Q1 2026 came in at 0.2%, up 1150.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.62% (up 1108.0% YoY), and the FY2025 annual result was 0.85%, down 14.0% from the prior year.
• Return on Sales came in at 0.2% for Q1 2026 at Bioadaptives, up from 0.79% in the prior quarter.
• In the past five years, Return on Sales ranged from a high of 0.03% in Q4 2023 to a low of 11.7% in Q1 2025.
• The 5-year median for Return on Sales is 0.49% (2025), against an average of 1.16%.
• Across the five-year window, Return on Sales slumped 1165 bps in 2025 and soared 1150 bps in 2026, its largest moves.
• Bioadaptives' Return on Sales stood at 0.1% in 2022, then soared by 127 bps to 0.03% in 2023, then slumped by 2044 bps to 0.52% in 2024, then slumped by 53 bps to 0.79% in 2025, then surged by 74 bps to 0.2% in 2026.
• The last three Return on Sales figures came in at 0.2% (Q1 2026), 0.79% (Q4 2025), and 0.82% (Q3 2025), per Business Quant data.